
|Articles|December 13, 2013
The Utility of the BRCAvantage Test
Author(s)Sukumar Nagendran, MD
Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.
Advertisement
Clinical Pearls
Sukumar Nagendran, MD, vice president, medical affairs, Quest Diagnostics, describes BRCAvantage, a test to detect BRCA1 and BRCA2 genes.
- BRCAvantage was launched in mid-October
- The test is a comprehensive solution to help patients and healthcare providers make clinical decisions regarding the prognostic nature of their disease course and treatment interventions
- BRCAvantage includes a complete analysis of BRCA1 and BRCA2 as well as targeted tests for other specific gene mutations and family gene mutations
<<<
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
NCCN Updates Breast Cancer Guidelines: Sacituzumab Govitecan for 1L TNBC
2
FDA Grants FTD to GPRC5D Bispecific LBL-034 for R/R Multiple Myeloma
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
5



















